###begin article-title 0
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 202 210 <span type="species:ncbi:9606">patients</span>
The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to therapy. Our goals were to investigate whether TUBB mutations and mismatch repair defects underlie paclitaxel and cisplatin resistance.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
Thirty-four patients with primary ovarian carcinomas (26 serous and eight clear cell carcinomas) treated with paclitaxel/cisplatin were analysed. TUBB exon 4 was analysed by nested PCR after a first round PCR using intronic primers. Microsatellite analysis was performed with the quasimonomorphic markers BAT 26 and BAT 34.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
Twenty-two of the 34 ovarian cancers (64.7%) presented residual tumour after surgery, seven of which (7/22; 31.8%) were shown to be chemoresistant (five serous and two clear cell tumours). Sequence analysis did not find any mutation in TUBB exon 4. Microsatellite instability was not detected in any of the ovarian carcinomas.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
We conclude that TUBB exon 4 mutations and mismatch repair defects do not play a significant role in paclitaxel/cisplatin resistance.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 58 59 58 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 51 56 <span type="species:ncbi:9606">women</span>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
Ovarian cancer is the fourth most common cancer in women [1]. The standard treatment for ovarian cancer is cytoreductive surgery followed by combination systemic chemotherapy [2]. Since the middle 90's, the combination paclitaxel/cisplatin became the standard chemotherapeutic treatment for poor prognosis ovarian cancer [3]. Nevertheless, some patients are resistant to this chemotherapeutic treatment, making it important to clarify the underlying mechanisms of resistance [4].
###end p 11
###begin p 12
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 394 398 384 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB</italic>
###xml 419 420 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 548 549 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 847 848 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 849 850 839 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1029 1030 1019 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1031 1032 1021 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
Paclitaxel binds to microtubules and causes kinetic suppression (stabilisation) of microtubule dynamics, promoting their polymerisation and cell cycle arrest in mitosis (antimitotic activity), which probably leads to apoptosis [5,6]. Microtubules are composed of a dimeric protein, tubulin, with alpha (alpha) and beta (beta) tubulin heterodimers in dynamic equilibrium. The beta-tubulin gene (TUBB), mapped to 6p21.3 [7], is composed of four exons and encodes a 445-aminoacid protein with GTPase function to which paclitaxel preferentially binds [8]. Cisplatin is activated intracellularly and establishes inter- and intra-strand DNA adducts that block replication and translation. The fate of cells after cisplatin exposure depends both on the extent of DNA damage and the cellular response to it, and apoptosis can be induced as a consequence [5,9]. Although the specific mechanism that triggers apoptosis is not totally clear, some evidence suggests that this process can be mediated by the DNA mismatch repair system (MMR) [5,9].
###end p 12
###begin p 13
###xml 227 229 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 230 232 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 354 356 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 357 359 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 464 469 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
Drug resistance is considered a multifactorial process, but the detailed mechanisms are still unknown. Recently, point mutations in the beta-tubulin gene, predominantly in exon 4, were associated with resistance to paclitaxel [10-12]. Resistance to cisplatin was linked with anomalies in the DNA MMR system resulting in microsatellite instability (MSI) [13-16]. In order to evaluate the relevance of these mechanisms to ovarian cancer chemoresistance, we screened TUBB exon 4 for mutations and performed MSI analysis in 34 ovarian carcinomas treated with paclitaxel/cisplatin and evaluated patients' response to chemotherapy.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient data
###end title 15
###begin p 16
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">Patients</span>
Thirty-four primary ovarian carcinoma patients, of serous (26 cases) or clear cell (eight cases) histological types (invasive or borderline), consecutively admitted at the Portuguese Oncology Institute - Porto and treated with the adjuvant chemotherapy scheme paclitaxel/cisplatin, were analysed. Patients previously treated with other chemotherapeutic regimens or radiotherapy were excluded from the study.
###end p 16
###begin p 17
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
Evaluation of treatment responses was done by an oncologist using computerized tomography or magnetic resonance and CA125 quantification, according to international guidelines [17]. Investigators performing laboratory analysis were not aware of chemotherapy response or resistance until the study was completed.
###end p 17
###begin title 18
DNA extraction
###end title 18
###begin p 19
###xml 605 606 604 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Genomic DNA was extracted from chemo-naive, paraffin embedded tumours, after dissection. Tissue blocks were sectioned, mounted on glass slides, deparaffinised, and stained with haematoxylin and eosin. Tumour areas were identified under the microscope on each slide and marked. Areas with at least 70% of cancer cells were identified on tissue sections. Selected paraffin blocks were sectioned (5mum sections) and mounted in microscope slides. Marked tumour areas were selected with a sterile razor blade. Three sections of tissue were incubated in a solution of 10 mM Tris-HCl buffer (pH 8.0), 2.5 mM MgCl2, 50 mM KCl, 0.5% (p/v) Tween 20, and 1 mg/mL proteinase K for 48 hours at 55degreesC.
###end p 19
###begin title 20
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
TUBB exon 4 sequencing
###end title 20
###begin p 21
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
For polymerase chain reaction (PCR) assays, different sets of oligonucleotides were designed to amplify specific regions of TUBB exon 4 that code for the GTP and paclitaxel binding sites. To assure that the amplicon was not a pseudogene, the following intronic primer set was used in the first round PCR: 5'AAG-GAG-ATA-CAT-CCG-AGG-GAA-TT3' and 5'AAG-GTA-TTC-ATG-ATG-CGA3'. After checking for first round PCR product in an agarose gel, a 1:10 dilution was used for nested PCRs with the following primers: set 1, 5'AGA-GAG-CTG-TGA-CTG-CCT-G3' and 5'AAG-GTA-TTC-ATG-ATG-CGA3'; set 2, 5'GCT-CTG-GAA-TGG-GCA-CTC3' and 5'CCG-TAG-GTT-GGT-TGT-GGT-CA3'; set 3, 5'CGG-GGA-TCT-GAA-CCA-CCT-T3' and 5'GAG-TGT-CAC-GGC-CTG-GAG-T3'. The PCR products were separated by electrophoresis in agarose gels stained with ethidium bromide and analysed in a transiluminator. All DNA samples were analysed in an automatic DNA sequencer ABI PRISM 310trade mark Genetic Analyser. The sequences were compared with the genomic sequence GenBank .
###end p 21
###begin title 22
MSI evaluation
###end title 22
###begin p 23
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
For microsatellite analysis, tumour DNA was amplified with primers for two quasimonomorphic markers BAT 26 (5'GAG-TGT-CAC-GGC-CTG-GAG-T3'; 5'AAC-CAT-TCA-ACA-TTT-TTA-ACC-C3') and BAT 34 (5'ACC-CTG-GAG-GAT-TTC-ATC-TC3'; 5'AAC-AAA-GCG-AGA-CCC-AGT-CT3') [18-20]. Fragments were analysed in an ABI PRISM 310trade mark Genetic Analyser.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Twenty-two of the 34 ovarian cancers (64.7%) presented residual tumour after surgery, seven of which (7/22; 31.8%) were shown to be chemoresistant (five serous and two clear cell tumours) (Table 1).
###end p 25
###begin p 26
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Amplicons of 700 bp were observed for all cases after amplification with the intronic primers (data not shown). Nested PCR with primer sets 1-3 specific for TUBB exon 4 resulted in amplicons with 129, 254, and 201 bp, respectively (Figure 1). Sequencing analysis of all 34 cases showed no TUBB exon 4 mutations (Figure 2).
###end p 26
###begin p 27
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
Microsatellite analysis with markers BAT 26 and BAT 34 (Figure 3) showed the normal pattern in all cases, so no evidence for microsatellite instability was detected in this series.
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Tumour resistance to chemotherapy or disease relapses resistant to further treatment after an initial response are common events in current cytotoxic cancer treatment regimens [5]. With regard to ovarian cancer chemotherapy, the current major challenge is to understand why histologically similar tumours behave so differently when treated with the same chemotherapeutic regimen. The action of a drug potentially depends on several mechanisms, namely, metabolisation, access into the tumour microenvironment, intracellular uptake, interaction with the target, and subsequent signalling events [5]. It is therefore important to study the different molecular mechanisms that can be involved in chemotherapy resistance.
###end p 29
###begin p 30
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 136 142 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 161 167 161 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 286 292 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 306 311 306 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 454 459 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
The rationale for studying the relationship between TUBB gene mutations with paclitaxel resistance came from the studies of Giannakakou et al and Gonzalez-Garay et al [10,11], who found TUBB mutations in ovarian cancer cell lines and in hamster cells, respectively. Subsequently, Monzo et al [12] reported TUBB mutations in 16 out of 36 (44.4%) paclitaxel resistant tumour samples from patients with advanced non-small cell lung cancer and proposed that TUBB mutations could represent a possible mechanism of paclitaxel resistance in that tumour type.
###end p 30
###begin p 31
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 177 183 177 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 477 482 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 603 609 603 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 695 701 695 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 702 704 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 747 753 747 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 788 793 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 861 866 861 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1066 1071 <span type="species:ncbi:9606">human</span>
However, our findings in the present study argue against a significant role of TUBB gene mutations in paclitaxel resistance in ovarian cancer. In keeping with our results, Sale et al [22] and Lamendola et al [23] did not detect TUBB gene mutations in ovarian cancer samples. Similar findings have recently been obtained for several other tumour types, namely, lung [24], breast [25,26], and gastric cancer [27]. Taken together, our and several other investigations concur that TUBB exon 4 mutations are not an important mechanism underlying paclitaxel resistance. To explain the early findings of Monzo et al [12], which were not reproduced by other authors, including the present study, Kelley et al [24] suggested that the primers used by Monzo et al [12] did not allow to discriminate TUBB from its pseudogenes [24]. Furthermore, the first studies reporting TUBB gene mutations were made in hamster cells [11] and in ovarian cancer cell lines [10] after selection by paclitaxel exposure, something that makes difficult a direct extrapolation of these findings to human tumours.
###end p 31
###begin p 32
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
We have also evaluated the MSI status of the 34 ovarian carcinomas with quasimonomorphic BAT 26 and BAT 34 markers, but did not find any microsatellite unstable tumours. Some authors have described an association between cisplatin resistance and MMR system anomalies in ovarian adenocarcinomas [28-30], as well as in colon cancer cell lines [31-33]. Additionally, other studies found MSI in ovarian cancer, namely, in serous and clear cell histological types [34-40]. However, the frequency of MSI identified in those studies was quite low (0-14.3%), which is in agreement with our findings. To completely rule out any relationship between deficient mismatch repair and cisplatin resistance, one would have to analyse more microsatellite markers in a larger series of tumours paired with normal DNA.
###end p 32
###begin title 33
Conclusion
###end title 33
###begin p 34
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
###xml 325 340 325 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P-glycoprotein </italic>
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 409 410 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 411 413 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 414 416 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 447 448 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 449 451 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 452 454 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 639 640 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 641 643 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 708 716 <span type="species:ncbi:9606">patients</span>
We conclude that, contrarily to earlier suggestions, TUBB exon 4 mutations and MMR defects are not major mechanisms underlying paclitaxel and/or cisplatin resistance in ovarian cancer. Further investigation on alternative mechanisms of resistance to these drugs is warranted. Possible mechanisms to paclitaxel resistance are P-glycoprotein overexpression [5,41], differential beta-tubulin isotype expression [5,42,43], and apoptosis deregulation [5,44-46]. Decrease in intracellular cisplatin level, increase of tolerance or repair of DNA lesions, and alterations in the apoptotic cascade have also been related with cisplatin resistance [5,47]. These studies are necessary to predict individual response of patients to these chemotherapeutic agents.
###end p 34
###begin title 35
Competing interests
###end title 35
###begin p 36
The author(s) declare that they have no competing interests.
###end p 36
###begin title 37
Authors' contributions
###end title 37
###begin p 38
BM carried out the molecular genetic studies and drafted the manuscript. IV participated in the design of the study and coordination. DP was responsible for clinical surveillance. AS was responsible for paraffin slides. IMP was responsible for the histopathologic analysis. CP carried out sequence alignment. MT coordinated the study. SC conceived the study and participated in its design and coordination.
###end p 38
###begin title 39
Pre-publication history
###end title 39
###begin p 40
The pre-publication history for this paper can be accessed here:
###end p 40
###begin p 41

###end p 41
###begin title 42
Acknowledgements
###end title 42
###begin p 43
We thank the Portuguese Health Ministry for the financial support (Project nr. 191/99). B. Mesquita was a fellow of Fundacao para Ciencia e Tecnologia. We thank Mariano Monzo and collaborators for useful discussions during this work.
###end p 43
###begin article-title 44
Cancer burden in the year 2000: the global picture
###end article-title 44
###begin article-title 45
The taxanes: an update
###end article-title 45
###begin article-title 46
###xml 89 94 <span type="species:ncbi:9606">women</span>
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results
###end article-title 46
###begin article-title 47
Chemotherapy in advanced ovarian cancer
###end article-title 47
###begin article-title 48
Ovarian cancer: strategies for overcoming resistance to chemotherapy
###end article-title 48
###begin article-title 49
Paclitaxel-induced cell death: where the cell cycle and apoptosis come together
###end article-title 49
###begin article-title 50
###xml 64 69 <span type="species:ncbi:9606">human</span>
An expressed tubulin gene, TUBB, is located on the short arm of human chromosome 6 and two related sequences are dispersed on chromosome 8 and 13
###end article-title 50
###begin article-title 51
Multiple forms of tubulin: different gene products and covalent modifications
###end article-title 51
###begin article-title 52
Cellular and molecular determinants of cisplatin resistance
###end article-title 52
###begin article-title 53
###xml 21 26 <span type="species:ncbi:9606">human</span>
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization
###end article-title 53
###begin article-title 54
A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance
###end article-title 54
###begin article-title 55
Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations
###end article-title 55
###begin article-title 56
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance
###end article-title 56
###begin article-title 57
Quoi de neuf sur la signification des instabilites microssatellitaires dans les pathologies tumorales humaines?
###end article-title 57
###begin article-title 58
The role of DNA mismatch repair in drug resistance
###end article-title 58
###begin article-title 59
Involvement of the DNA mismatch repair system in antineoplastic drug resistance
###end article-title 59
###begin article-title 60
General principles of chemotherapy
###end article-title 60
###begin article-title 61
BAT - 26, an indicator of the replication error phenotype in colorectal cancers and cell lines
###end article-title 61
###begin article-title 62
###xml 52 57 <span type="species:ncbi:9606">human</span>
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites
###end article-title 62
###begin article-title 63
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterization of the human P53 gene
###end article-title 63
###begin article-title 64
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology
###end article-title 64
###begin article-title 65
###xml 49 54 <span type="species:ncbi:9606">human</span>
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers
###end article-title 65
###begin article-title 66
Beta tubulin mutations are rare in ovarian carcinoma
###end article-title 66
###begin article-title 67
Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer
###end article-title 67
###begin article-title 68
###xml 56 61 <span type="species:ncbi:9606">human</span>
Mutational analysis of the class I beta-tubulin gene in human breast cancer
###end article-title 68
###begin article-title 69
Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer
###end article-title 69
###begin article-title 70
Absence of beta-tubulin gene mutation in gastric carcinoma
###end article-title 70
###begin article-title 71
###xml 23 28 <span type="species:ncbi:9606">human</span>
Genetic instability in human ovarian cancer cell lines
###end article-title 71
###begin article-title 72
Loss of DNA mismatch repair in acquired resistance to cisplatin
###end article-title 72
###begin article-title 73
Enrichment for DNA mismatch repair deficient cells during treatment with cisplatin
###end article-title 73
###begin article-title 74
The role of DNA mismatch repair in platinum drug resistance
###end article-title 74
###begin article-title 75
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells
###end article-title 75
###begin article-title 76
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 13 21 13 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
###end article-title 76
###begin article-title 77
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH2 </italic>
###xml 64 69 <span type="species:ncbi:9606">human</span>
Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer
###end article-title 77
###begin article-title 78
Genetic alterations distinguish different types of ovarian tumors
###end article-title 78
###begin article-title 79
Microsatellite instability differences between familial and sporadic ovarian cancers
###end article-title 79
###begin article-title 80
Microsatellite analysis in serous tumors of the ovary
###end article-title 80
###begin article-title 81
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma
###end article-title 81
###begin article-title 82
Microsatellite instability and alteration of the expression of the hMLH1 and hMSH2 in ovarian clear cell carcinoma
###end article-title 82
###begin article-title 83
Different types of microsatellite instability in ovarian carcinoma
###end article-title 83
###begin article-title 84
###xml 97 102 <span type="species:ncbi:9606">human</span>
Acquisition of taxol resistance via P-glycoprotein and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells
###end article-title 84
###begin article-title 85
###xml 64 69 <span type="species:ncbi:9606">human</span>
Altered beta-tubulin isotype expression in paclitaxel resistant human prostate carcinoma cells
###end article-title 85
###begin article-title 86
Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol
###end article-title 86
###begin article-title 87
Bcl2 is the guardian of microtubule integrity
###end article-title 87
###begin article-title 88
Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis
###end article-title 88
###begin article-title 89
BAX protein expression and clinical outcome in epithelial ovarian cancer
###end article-title 89
###begin article-title 90
Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to taxol
###end article-title 90
###begin title 91
Figures and Tables
###end title 91
###begin p 92
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
Nested PCR products (in duplicate) obtained with the three primer sets specific for TUBB exon 4 in an ovarian carcinoma (from right to left, lane 1: 100 bp step ladder; lanes 2 and 3: 129 bp amplicon - set 1 primers; lanes 4 and 5: 254 bp amplicon - set 2 primers; lanes 6 and 7: 201 bp amplicon - set 3 primers).
###end p 92
###begin p 93
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TUBB </italic>
Electrophorogram of part of TUBB exon 4 without any sequence variation in an ovarian carcinoma.
###end p 93
###begin p 94
Electrophorograms of BAT 26 (A) and BAT 34 (B) markers in an ovarian carcinoma, showing the same pattern found in normal control DNA.
###end p 94
###begin p 95
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Clinical, pathological and genetic data of 34 ovarian cancer patients.
###end p 95
###begin p 96
###xml 136 177 136 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Federation Internationale de Gynecologie </italic>
B: borderline tumours; CR: complete response; PR: partial response; WR: without response. The stage classification was according to the Federation Internationale de Gynecologie [21] and grading was defined as well differentiated (1), moderately differentiated (2), and poorly differentiated (3).
###end p 96

